Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,747 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Low dose Placebo Clear all
Completed Phase 2 Interventional

A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma

NCT01987492
View directory record Official record
Conditions
Asthma
Interventions
Lebrikizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 75 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Bakersfield, California • Long Beach, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 21, 2017 · Synced Sep 24, 2026, 4:27 AM EDT
Terminated Early Phase 1 Interventional Results available

Low Dose Vasopressin in Traumatic Shock

NCT00420407
View directory record Official record
Conditions
Injuries, Shock, Traumatic
Interventions
normal saline control, vasopressin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 1 Interventional

Study to Evaluate DNL201 in Subjects With Parkinson's Disease

NCT03710707
View directory record Official record
Conditions
Parkinson Disease
Interventions
DNL201, Placebo
Drug
Lead sponsor
Denali Therapeutics Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Long Beach, California • Aurora, Colorado • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 4 Interventional Results available

EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)

NCT02816736
View directory record Official record
Conditions
Heart Failure
Interventions
LCZ696, valsartan, LCZ696 placebo, valsartan placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 85 Years
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
38
States / cities
Beverly Hills, California • Sacramento, California • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Not applicable Interventional

Effect of Supplement on Appetite and GLP-1

NCT06790771
View directory record Official record
Conditions
Hunger
Interventions
High Dose Supplement, Low Dose Supplement, Placebo
Dietary Supplement
Lead sponsor
Texas Christian University
Other
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 1 Interventional

Study of VX-985 in Subjects With Chronic Hepatitis C

NCT01144936
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
VX-985 or matching placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 64 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Overland Park, Kansas • Baltimore, Maryland • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Mar 8, 2011 · Synced Sep 24, 2026, 4:27 AM EDT
Terminated Phase 3 Interventional Results available

221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

NCT02477800
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Aducanumab (BIIB037), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 85 Years
Enrollment
1,653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
59
States / cities
Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 52 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 2 Interventional Results available

Acetylsalicylic Acid Compared to Placebo in Treating High-Risk Patients With Subsolid Lung Nodules

NCT02169271
View directory record Official record
Conditions
Current Smoker, Former Smoker, Multiple Pulmonary Nodules, Tobacco Use Disorder
Interventions
Aspirin, Laboratory Biomarker Analysis, Placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
50 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 2 Interventional Results available

Effect of Milnacipran in Chronic Neuropathic Low Back Pain

NCT01225068
View directory record Official record
Conditions
Low Back Pain
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults

NCT03205917
View directory record Official record
Conditions
HIV Infections
Interventions
PGDM1400/Placebo (3mg/kg IV), PGDM1400/Placebo (10mg/kg IV), PGDM1400/Placebo (30mg/kg IV), PGDM1400 + PGT121/Placebo (3mg/kg + 3mg/kg IV), PGDM1400 + PGT121/Placebo (10mg/kg + 10mg/kg IV), PGDM1400 + PGT121/Placebo (30mg/kg + 30mg/kg IV), PGDM1400 + PGT121 + VRC07-523LS (20mg/kg + 20mg/kg + 20 mg/kg IV), PGDM1400 + PGT121 (MTD IV)
Biological
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 13, 2020 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 3 Interventional Results available

Hydrocortisone for BPD

NCT01353313
View directory record Official record
Conditions
Infant, Newborn, Infant, Small for Gestational Age, Infant, Very Low Birth Weight, Infant, Premature, Bronchopulmonary Dysplasia
Interventions
Hydrocortisone, Placebo
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 30 Weeks
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Processed Orange and the Glycemic Response

NCT02112851
View directory record Official record
Conditions
Maximum Observed Plasma Glucose Concentration (Cmax)
Interventions
Orange flavored beverage
Other
Lead sponsor
PepsiCo Global R&D
Industry
Eligibility
30 Years to 65 Years · Male only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis

NCT03224351
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-659, TEZ/IVA, IVA, Placebo (matched to VX-659/TEZ/IVA), TEZ, VX-561, Placebo (matched to VX-659/TEZ/VX-561)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
25
States / cities
New Haven, Connecticut • Miami, Florida • Morton Grove, Illinois + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Sep 24, 2026, 4:27 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Curcumin & Astaxanthin for Lowering Triglyceride Readings and Inflammation

NCT07063056
View directory record Official record
Conditions
Triglycerides
Interventions
Curcumin (Longvida™), Half Dose Curcumin (Longvida™), Astaxanthin, Placebo Control
Dietary Supplement · Other
Lead sponsor
Medinutra LLC
Other
Eligibility
21 Years to 59 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Dublin, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 2 Interventional Results available

Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

NCT03340675
View directory record Official record
Conditions
Duchenne Muscular Dystrophy Cardiomyopathy, Cardiomyopathy, Dilated
Interventions
Ifetroban, Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
7 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
10
States / cities
Little Rock, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.

NCT02108262
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
CSL112, Placebo
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
1,267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
48
States / cities
Birmingham, Alabama • Huntsville, Alabama • Concord, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2021 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis

NCT03594227
View directory record Official record
Conditions
Alopecia
Interventions
ATI-501 400mg BID (Low dose), ATI-501 600mg BID (Mid dose), ATI-501 800mg BID (High dose), Placebo
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
25
States / cities
Hot Springs, Arkansas • Rogers, Arkansas • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Sep 24, 2026, 4:27 AM EDT
Recruiting Phase 4 Interventional

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis

NCT04314375
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Low Dose Budesonide, High Dose Budesonide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
5 Years to 17 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Garden Grove, California • Indianapolis, Indiana • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 3 Interventional

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery

NCT00679588
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Semuloparin Sodium, Enoxaparin sodium, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
4,413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Corlton, California • Huntingdon Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2013 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises

NCT01895361
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
SelG1, Placebo
Drug
Lead sponsor
Reprixys Pharmaceutical Corporation
Industry
Eligibility
16 Years to 65 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
49
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 2 Interventional Results available

Citalopram for Cocaine Dependence

NCT01535573
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Citalopram, Placebo
Drug
Lead sponsor
Joy Schmitz
Other
Eligibility
18 Years to 60 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Sep 24, 2026, 4:27 AM EDT
Not listed Not applicable Interventional

Prevention of Posttraumatic Stress Disorder (PTSD) With Early Hydrocortisone Treatment: Pilot

NCT00597857
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Hydrocortisone, placebo
Drug
Lead sponsor
Kent State University
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 27, 2009 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 2 Interventional Results available

Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure

NCT02235077
View directory record Official record
Conditions
Heart Failure
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
21 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
22
States / cities
Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both

NCT05260021
View directory record Official record
Conditions
Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D, T2DM (Type 2 Diabetes Mellitus), Glucose Metabolism Disorders, Endocrine System Diseases, Metabolic Disease
Interventions
Tirzepatide Dose 1, Tirzepatide Dose 2, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
10 Years to 18 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Sep 24, 2026, 4:27 AM EDT